Sana Biotechnology reported that the 14‑month follow‑up of its investigator‑sponsored first‑in‑human study of the UP421 islet product confirms the transplanted cells survived and produced insulin without the need for immunosuppression. The study involved a single type 1 diabetes patient and demonstrated that the HIP‑engineered islets maintained function and engraftment for more than a year, providing the first human evidence that Sana’s hypoimmune platform can eliminate lifelong immunosuppressive therapy in islet transplantation.
C‑peptide measurements taken at 14 months were comparable to those recorded in the first six months and exceeded levels observed at months 9 and 12, indicating sustained beta‑cell activity. The data also showed no safety signals, reinforcing the platform’s immune‑evading properties and the patient’s stable glycemic control without exogenous insulin injections.
The results reinforce Sana’s strategic focus on SC451, its stem‑cell‑derived islet program, and support the company’s plan to file an IND for SC451 and initiate a Phase 1 trial as early as 2026. The company’s regulatory strategy has been strengthened by recent FDA interactions, and the 14‑month data provide a critical milestone that could accelerate the IND filing and subsequent clinical development of SC451.
Sana’s cash reserves of $138 million are projected to fund operations into late 2026, but the company’s negative free‑cash‑flow of $145 million over the last twelve months highlights a significant burn rate. Despite the clinical success, the market reaction was modest, with a 9 % gain on the announcement day, reflecting investor caution amid the company’s ongoing financial headwinds and a 24 % year‑to‑date decline in share price.
"These findings build upon previously presented data and continue to show no safety issues, along with continued immune evasion, survival, and function of the transplanted cells," said Per‑Ola Carlsson, principal investigator and professor at Uppsala University Hospital. "Importantly, the results demonstrate the positive impact of improved glucose control on beta cell function and the dynamic functional capacity of beta cells transplanted in a single low dose without immunosuppression. This work suggests that the hypoimmune technology has the potential to enable a functional cure for type 1 diabetes without immunosuppression, and we look forward to working with Sana as it brings forward SC451, a more scalable approach, at higher doses," an unnamed source added. "With these data and our progress in manufacturing, we are increasingly optimistic about the potential for SC451 – a gene‑modified, stem‑cell‑derived pancreatic islet cell therapy with a goal of single treatment that leads to normal blood glucose with no more insulin injections or immunosuppression," said Steve Harr, President and CEO of Sana.
Sana’s differentiation from competitors such as CellTrans’ Lantidra and Vertex’s VX‑880 is clear: those products still require immunosuppression, whereas Sana’s HIP platform eliminates that requirement. The 14‑month data therefore position Sana ahead of the field in terms of safety and long‑term efficacy, potentially accelerating its path to a functional cure for type 1 diabetes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.